Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors

Area of Science:

• Oncology
• Biotechnology
• Nanomedicine

Background:

• Multidrug resistance (MDR) in cancer presents a significant clinical hurdle, particularly in solid tumors, due to complex contributing factors.
• Genetic profiling of MDR tumors offers potential for targeted therapies like RNA interference (RNAi).
• Effective in vivo delivery of nucleic acid constructs (siRNAs, miRNAs) faces substantial barriers, limiting clinical translation.

Purpose of the Study:

• To review the principles and mechanisms of RNA interference (RNAi) for cancer therapy.
• To discuss the barriers hindering the clinical application of RNAi.
• To explore nanoparticle-based strategies for active and passive tumor targeting and delivery of RNAi agents and gene-drug combinations.

Main Methods:

• Review of RNA interference (RNAi) principles and mechanisms.
• Discussion of barriers to in vivo nucleic acid delivery.
• Analysis of nanoparticle systems for active and passive tumor targeting.
• Examination of examples using miRNA, siRNA, and gene-drug combinations delivered via nanoparticles.

Main Results:

• RNA interference (RNAi) offers a mechanism for targeted cancer therapy by interfering with gene expression.
• Significant barriers impede the in vivo delivery of functional RNAi agents, including siRNAs and miRNAs.
• Nanoparticle systems demonstrate potential for overcoming delivery challenges through active and passive tumor targeting.
• Combination therapies involving miRNAs, siRNAs, and drugs, delivered via nanoparticles, show promise for treating MDR cancers.

Conclusions:

• RNA interference (RNAi) holds therapeutic potential for multidrug-resistant (MDR) cancers.
• Nanoparticle-mediated delivery systems are crucial for overcoming in vivo delivery barriers of RNAi agents.
• Targeted delivery of RNAi therapeutics, including miRNAs and siRNAs, via nanoparticles is a promising strategy for enhancing cancer treatment outcomes.